The FDA has approved Shield (Guardant), a DNA blood test, for colorectal cancer (CRC) screening in average-risk adults ≥45 years old. Shield is the second blood-based DNA test to be approved for CRC…
Med Lett Drugs Ther. 2025 Jun 9; 67(1730):90-2 doi:10.58347/tml.2025.1730b
The FDA has approved Shield (Guardant), a DNA blood test, for colorectal cancer (CRC) screening in average-risk adults ≥45 years old. Shield is the second blood-based DNA test to be approved for CRC screening; ColoHealth (formerly Epi proColon) was approved in 2016.
The FDA has approved Cologuard Plus (Exact Sciences), a new at-home multitarget stool DNA test, for colorectal cancer (CRC) screening in average-risk adults ≥45 years old. Cologuard , the first FDA-approved…
Med Lett Drugs Ther. 2025 May 12; 67(1728):73-5 doi:10.58347/tml.2025.1728a
The FDA has approved Cologuard Plus (Exact Sciences), a new at-home multitarget stool DNA test, for colorectal cancer (CRC) screening in average-risk adults ≥45 years old. Cologuard , the first FDA-approved multitarget stool DNA test, has been available since 2014.
The RAS GTPase family inhibitor adagrasib ( Krazati – BMS), which received accelerated approval for treatment of KRAS G12C (glycine-to-cysteine mutation at codon 12)-mutated locally advanced or metastatic…
Med Lett Drugs Ther. 2024 Aug 19; 66(1709):e137-8 doi:10.58347/tml.2024.1709f
The RAS GTPase family inhibitor adagrasib ( Krazati – BMS), which received accelerated approval for treatment of KRAS G12C (glycine-to-cysteine mutation at codon 12)-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in 2022, has now received accelerated approval from the FDA for use with cetuximab for treatment of KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC) in adults who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Adagrasib is the first KRAS inhibitor to be approved in the US for treatment of CRC.
Fruquintinib ( Fruzaqla – Takeda), an oral kinase inhibitor, has been approved by the FDA for treatment of adults with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin-,…
Med Lett Drugs Ther. 2024 Feb 19; 66(1696):e34-5 doi:10.58347/tml.2024.1696f
Fruquintinib ( Fruzaqla – Takeda), an oral kinase inhibitor, has been approved by the FDA for treatment of adults with metastatic colorectal cancer (mCRC) who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, anti-VEGF therapy, and, in patients with RAS wild-type mutations, anti-EGFR therapy. The drug can be used in patients with mCRC regardless of biomarker status. Fruquintinib is the first drug to become available in the US for treatment of mCRC that targets 3 VEGF receptor kinases.
The FDA has approved Suflave (Sebela/Braintree), a low-volume polyethylene glycol (PEG)- and sulfate-based product for cleansing of the colon prior to colonoscopy in adults. Other oral colonoscopy preparations…
Med Lett Drugs Ther. 2023 Sep 18; 65(1685):148-51 doi:10.58347/tml.2023.1685b
The FDA has approved Suflave (Sebela/Braintree), a low-volume polyethylene glycol (PEG)- and sulfate-based product for cleansing of the colon prior to colonoscopy in adults. Other oral colonoscopy preparations available in the US are listed in Table 2. Suflave is marketed as tasting better than other products.
The FDA has approved an oral tablet formulation of sodium sulfate, magnesium sulfate, and potassium chloride ( Sutab – Braintree) for colon cleansing prior to colonoscopy in adults. A sodium sulfate-based…
Med Lett Drugs Ther. 2021 Mar 8; 63(1619):33-6
The FDA has approved an oral tablet formulation of sodium sulfate, magnesium sulfate, and potassium chloride ( Sutab – Braintree) for colon cleansing prior to colonoscopy in adults. A sodium sulfate-based oral solution (Suprep) has been available in the US since 2010. Sutab is the second tablet formulation to be approved for bowel cleansing prior to colonoscopy; a sodium phosphate-based tablet (OsmoPrep) was approved earlier.
The FDA has approved the oral kinase inhibitor encorafenib ( Braftovi – Pfizer), in combination with the epidermal growth factor receptor (EGFR) inhibitor cetuximab (Erbitux) , for treatment of adults with…
Med Lett Drugs Ther. 2021 Jan 25; 63(1616):15-6
The FDA has approved the oral kinase inhibitor encorafenib ( Braftovi – Pfizer), in combination with the epidermal growth factor receptor (EGFR) inhibitor cetuximab (Erbitux) , for treatment of adults with metastatic colorectal cancer (CRC) with a BRAF V600E mutation. Encorafenib was approved in 2018 for use with the mitogen-activated kinase (MEK) inhibitor binimetinib (Mektovi) for treatment of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation.
In our article in issue 1564 on Plenvu for colonoscopy preparation (Med Lett Drugs Ther 2019; 61:11) , the comparator drug in the DAYB trial was not Prepopik , but rather Citrafleet , a similar sodium…
Med Lett Drugs Ther. 2019 Jul 29; 61(1577):120
In our article in issue 1564 on Plenvu for colonoscopy preparation (Med Lett Drugs Ther 2019; 61:11) , the comparator drug in the DAYB trial was not Prepopik , but rather Citrafleet , a similar sodium picosulfate-based preparation that is not available in the US. Also, we said that Plenvu can be taken as a single- or split-dose regimen; we should have said that it can be taken as two doses in a single day or split over two days.
Most colorectal cancers arise from localized adenomatous polyps in a process that may take 10 years or more. Early detection and removal of a precancerous colonic lesion (polyp) can prevent cancer from…
Med Lett Drugs Ther. 2019 Jul 1; 61(1575):97-9
Most colorectal cancers arise from localized adenomatous polyps in a process that may take 10 years or more. Early detection and removal of a precancerous colonic lesion (polyp) can prevent cancer from developing.
The FDA has approved Plenvu (Salix), a polyethylene glycol (PEG)-containing oral powder for reconstitution, for colon cleansing prior to colonoscopy in adults. Plenvu is the first PEG-containing colonoscopy…
Med Lett Drugs Ther. 2019 Jan 28; 61(1564):11-4
The FDA has approved Plenvu (Salix), a polyethylene glycol (PEG)-containing oral powder for reconstitution, for colon cleansing prior to colonoscopy in adults. Plenvu is the first PEG-containing colonoscopy preparation that requires only 1 L of water for dissolution and ingestion of 1 L of clear fluid in addition.
The FDA has approved Clenpiq (Ferring), a low-volume oral solution that contains sodium picosulfate, magnesium oxide, and anhydrous citric acid, for colon cleansing prior to colonoscopy in adults. The…
Med Lett Drugs Ther. 2018 May 21; 60(1547):84-6
The FDA has approved Clenpiq (Ferring), a low-volume oral solution that contains sodium picosulfate, magnesium oxide, and anhydrous citric acid, for colon cleansing prior to colonoscopy in adults. The ready-to-drink solution contains the same ingredients as Prepopik , which is supplied as a powder for reconstitution.
The immune checkpoint inhibitor pembrolizumab ( Keytruda – Merck), a programmed death receptor-1 (PD-1) inhibitor, has been granted accelerated approval by the FDA for use in adults and children who have…
The FDA has approved the pyrimidine analog uridine triacetate ( Vistogard – Wellstat Therapeutics) for emergency treatment of a fluorouracil (5-FU) or capecitabine ( Xeloda , and generics) overdose or severe…
The FDA has approved Lonsurf (Taiho Oncology), a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil, for oral treatment of metastatic…
Regorafenib ( Stivarga – Bayer), a multikinase inhibitor, has been approved by the FDA for treatment of patients with metastatic colorectal cancer previously treated with multiple other regimens specified in…
Med Lett Drugs Ther. 2013 Apr 29; 55(1415):36
Regorafenib ( Stivarga – Bayer), a multikinase inhibitor, has been approved by the FDA for treatment of patients with metastatic colorectal cancer previously treated with multiple other regimens specified in the labeling. It has also been approved for use in treatment-refractory, locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST).
Ziv-aflibercept ( Zaltrap – Sanofi/Regeneron), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA for use in combination with 5-fluorouracil, leucovorin and irinotecan…
Med Lett Drugs Ther. 2013 Apr 29; 55(1415):36
Ziv-aflibercept ( Zaltrap – Sanofi/Regeneron), a vascular endothelial growth factor (VEGF) inhibitor, has been approved by the FDA for use in combination with 5-fluorouracil, leucovorin and irinotecan (FOLFIRI) for treatment of metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. It is the same drug as aflibercept, which was approved last year as an intravitreal injection (Eylea) for treatment of neovascular (wet) agerelated macular degeneration (AMD). Ziv-aflibercept is the second VEGF inhibitor approved for treatment of metastatic colorectal cancer; bevacizumab (Avastin) , given in addition to chemotherapy, is a standard firstand second-line therapy.
Colonoscopy remains the preferred method of colorectal cancer screening. Many patients consider cleansing the bowel in preparation for colonoscopy the most unpleasant part of the procedure, but inadequate…
Med Lett Drugs Ther. 2013 Jan 21; 55(1408):6-7
Colonoscopy remains the preferred method of colorectal cancer screening. Many patients consider cleansing the bowel in preparation for colonoscopy the most unpleasant part of the procedure, but inadequate bowel preparation significantly lowers the diagnostic yield.
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may improve outcomes. Screening tests for some common cancers are reviewed below.
Treat Guidel Med Lett. 2012 Dec; 10(124):87-94
Use of screening tests to identify cancers before they cause symptoms can lead to earlier therapy and may improve outcomes. Screening tests for some common cancers are reviewed below.
Panitumumab ( Vectibix - Amgen), a fully human IgG 2 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), has been approved by the FDA for treatment of patients with EGFR-expressing…
Med Lett Drugs Ther. 2007 Apr 23; 49(1259):35-6
Panitumumab ( Vectibix - Amgen), a fully human IgG 2 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), has been approved by the FDA for treatment of patients with EGFR-expressing metastatic colorectal cancer that has progressed despite standard chemotherapy. It is the second monoclonal antibody EGFR inhibitor to be approved for metastatic colorectal cancer; cetuximab (Erbitux) , a human-murine chimeric IgG 1 monoclonal antibody, was approved in 2004.
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and…
Treat Guidel Med Lett. 2006 Aug; 4(48):55-60
A variety of cancer chemotherapy drugs are used, mostly in combination, for treatment of locally advanced and metastatic esophageal, gastric and colorectal cancers. The mechanism of action, indications and adverse effects of some of these drugs are discussed in thei article.
The FDA has approved a new genetic test to identify patients who may be at increased risk of severe toxicity when treated with the cancer chemotherapy drug irinotecan (Camptosar) . The Invader UGT1A1 Molecular…
Med Lett Drugs Ther. 2006 May 8; 48(1234):40
The FDA has approved a new genetic test to identify patients who may be at increased risk of severe toxicity when treated with the cancer chemotherapy drug irinotecan (Camptosar) . The Invader UGT1A1 Molecular Assay (Third Wave Technologies) detects the UGT1A1*28 allele, a variation in the uridine diphosphate glucuronosyltranferase 1A1 (UGT1A1) gene. The FDA recently revised the safety labeling for irinotecan, recommending that the dosing of irinotecan be reduced for patients who are homozygous for the UGT1A1*28 allele.
Currently available techniques for colorectal cancer screening include fecal occult-blood testing, flexible sigmoidoscopy, double contrast barium enema (DCBE) and traditional optical colonoscopy. Optical…
Med Lett Drugs Ther. 2005 Feb 14; 47(1202):15-6
Currently available techniques for colorectal cancer screening include fecal occult-blood testing, flexible sigmoidoscopy, double contrast barium enema (DCBE) and traditional optical colonoscopy. Optical colonoscopy requires bowel cleansing and sedation, and involves some risk, but is generally accepted as the best available method for detection of lesions and offers the advantage that polyps can be removed when they are identified. A less invasive screening tool, computed tomography (CT) colonography, also known as virtual colonoscopy (VC), offers an additional option.
Cetuximab ( Erbitux - ImClone Systems/Bristol-Myers Squibb), an epidermal growth factor receptor (EGFR) inhibitor, and bevacizumab ( Avastin - Genentech), the first vascular endothelial growth factor…
Med Lett Drugs Ther. 2004 Jun 7; 46(1184):46-8
Cetuximab ( Erbitux - ImClone Systems/Bristol-Myers Squibb), an epidermal growth factor receptor (EGFR) inhibitor, and bevacizumab ( Avastin - Genentech), the first vascular endothelial growth factor angiogenesis inhibitor, have recently been approved by the FDA for treatment of patients with metastatic colorectal cancer. Cetuximab is approved for treatment of patients with EGFR-expressing tumors, either in combination regimens with irinotecan ( Camptosar )when the cancer has progressed on irinotecan-based therapy, or as monotherapy for those who cannot tolerate irinotecan. Bevacizumab is approved for first-line therapy in combination with a fluorouracil-based regimen.
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants.…
Treat Guidel Med Lett. 2003 Mar; 1(7):41-52
The tables in this article list drugs used for treatment of cancer in the USA and Canada and their major adverse effects. The choice of drugs in Table I is based on the opinions of Medical Letter consultants. Some drugs are listed for indications for which they have not been approved by the US Food and Drug Administration. In some cases, such as elderly patients or those with many co-morbid illnesses, the regimen of choice might not be suitable. For many of the cancers listed, surgery and/or radiation therapy may be the treatment of choice or may also be part of the management. Anticancer drugs and their adverse effects are listed in Table II on page 46. A partial list of brand names appears on page 52.
Oxaliplatin ( Eloxatin -Sanofi-Synthelabo) has been approved by the FDA for use in combination with fluorouracil (5-FU; Adrucil , and others) and leucovorin (LV; Wellcovorin ) for patients with metastatic…
Med Lett Drugs Ther. 2003 Jan 20; 45(1148):7-8
Oxaliplatin ( Eloxatin -Sanofi-Synthelabo) has been approved by the FDA for use in combination with fluorouracil (5-FU; Adrucil , and others) and leucovorin (LV; Wellcovorin ) for patients with metastatic colorectal cancer whose disease has recurred or progressed despite treatment with 5-FU/LV plus irinotecan ( Camptosar - Medical Letter 1997; 39:8).
Irinotecan hydrochloride ( Camptosar - Pharmacia & Upjohn; formerly CPT-11) has been approved by the US Food and Drug Administration for treatment of metastatic colorectal cancer refractory to other drugs…
Med Lett Drugs Ther. 1997 Jan 19; 39(992):8
Irinotecan hydrochloride ( Camptosar - Pharmacia & Upjohn; formerly CPT-11) has been approved by the US Food and Drug Administration for treatment of metastatic colorectal cancer refractory to other drugs including fluorouracil (5-FU; Adrucil and others).